


10-2202

1645\$  
Box 509

<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>			Docket No. BMID9913US		
Applicant(s): Thomas EMRICH, et al.					
Serial No. 09/284,787	Filing Date April 20, 1999	Examiner Robert Zeman	Group Art Unit 1645		
Invention: MONOCLONAL ANTIBODIES AGAINST THE EPITOPE YPYDVPDYA, A PROCESS FOR THEIR PRODUCTION AND THEIR USE					
<u>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	8 -	20 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	3 -	3 =	0 x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
<div><input checked="" type="checkbox"/> No additional fee is required for amendment.</div> <div><input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed.</div> <div><input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed.</div> <div><input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0877 A duplicate copy of this sheet is enclosed.</div> <div><input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.</div> <div><input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</div>					
<div> Signature</div>			Dated: October 21, 2002		
Kenneth J. Waite, Reg. No. 45,189 Roche Diagnostics Corporation 9115 Hague Road, Bldg D P.O. B x 50457 Indianapolis, IN 46250-0457 Telephone: (317) 521-3104 Facsimile: (317) 521-2883			<div>I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.</div> <div>Signature of Person Mailing Correspondence</div> <div>Typed or Printed Name of Person Mailing Correspondence</div>		
CC:					

TRADEMARK OFFICE  
OCT 21 2002

RECEIVED  
OCT 25 2002  
TECH CENTER 1600/2800

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): Thomas EMRICH et al.

Docket No.

BMID9913US

Serial No.

09/284,787

Filing Date

August 16, 1999

Examiner

Robert Zeman

Group Art Unit

1645

Invention: MONOCLONAL ANTIBODIES AGAINST THE EPITOPE YPYDVPDYA, A PROCESS FOR THEIR PRODUCTION AND THEIR USE

RECEIVED  
OCT 25 2002  
TECH CENTER 1600/2900



I hereby certify that this Amendment and Response, Extension and Sequence Listing  
(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Commissioner of Patents and Trademarks, Washington, D.C.

20231-0001 on October 21, 2002  
(Date)

Michele Wilson

(Typed or Printed Name of Person Mailing Correspondence)

A handwritten signature in cursive script that reads "Michele Wilson".

(Signature of Person Mailing Correspondence)

EL841986284US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.



Attorney Docket No. BMID 9913US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Thomas EMRICH, *et al.*

Application No.: 09/284,787

Group No.: 1645

Filed: August 16, 1999

Examiner: Robert Zeman

For: Monoclonal Antibodies Against The Epitope YPYDVPDYA, A Process For Their Production And Their Use

Assistant Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT BY ATTORNEY OF RECORD REGARDING BIOLOGICAL DEPOSIT**

I, Kenneth J. Waite, Attorney of Record in the above-captioned matter, hereby state to the best of my knowledge and belief, the following:

1. On October 8, 1996, the hybridoma cell line designated as R3A12 was deposited under the terms of the Budapest Treaty at the Deutsche Sammlung für Mikroorganismen und Zellkulturen ("DSMZ") under the Accession number DSM AC2286
2. This deposit is demonstrated by the attached documents, pages 18 and 20 from the originally filed PCT application pertaining to the above-captioned matter.

RECEIVED

OCT 25 2002

TECH CENTER 1600/2900

3. All restrictions imposed by depositor on the availability to the public of the deposited material will be removed upon the granting of a patent requiring the use of this material.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'KJ Waite', written over a horizontal line.

Date: Monday, Oct 21, 2002

Kenneth J. Waite, Reg. NO. 45,189  
Roche Diagnostics Corporation  
9115 Hague Road, Bldg. D  
Indianapolis, IN 46250-0457  
Telephone: (317) 521-3104  
Fax: (317) 521-2883